- Home
- TLRY vs EVO Comparison
TLRY vs EVO Comparison
Compare TLRY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- EVO
- Stock Information
- Founded
- TLRY N/A
- EVO 1993
- Country
- TLRY Canada
- EVO Germany
- Employees
- TLRY N/A
- EVO N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- EVO Health Care
- Exchange
- TLRY Nasdaq
- EVO Nasdaq
- Market Cap
- TLRY 1.3B
- EVO 1.5B
- IPO Year
- TLRY 2018
- EVO 2021
- Fundamental
- Price
- TLRY $1.20
- EVO $4.11
- Analyst Decision
- TLRY Hold
- EVO Buy
- Analyst Count
- TLRY 3
- EVO 2
- Target Price
- TLRY $1.88
- EVO $5.90
- AVG Volume (30 Days)
- TLRY 43.8M
- EVO 184.0K
- Earning Date
- TLRY 01-10-2025
- EVO 11-06-2024
- Dividend Yield
- TLRY N/A
- EVO N/A
- EPS Growth
- TLRY N/A
- EVO N/A
- EPS
- TLRY N/A
- EVO N/A
- Revenue
- TLRY $829,216,000.00
- EVO $866,665,179.00
- Revenue This Year
- TLRY $16.98
- EVO $3.89
- Revenue Next Year
- TLRY $5.96
- EVO $9.65
- P/E Ratio
- TLRY N/A
- EVO N/A
- Revenue Growth
- TLRY 18.38
- EVO N/A
- 52 Week Low
- TLRY $1.14
- EVO $2.85
- 52 Week High
- TLRY $2.97
- EVO $8.39
- Technical
- Relative Strength Index (RSI)
- TLRY 40.97
- EVO 42.87
- Support Level
- TLRY $1.15
- EVO $4.00
- Resistance Level
- TLRY $1.23
- EVO $4.63
- Average True Range (ATR)
- TLRY 0.08
- EVO 0.14
- MACD
- TLRY -0.02
- EVO -0.04
- Stochastic Oscillator
- TLRY 13.51
- EVO 16.88
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.